Published in J Clin Microbiol on December 18, 2013
Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis. Nat Commun (2015) 1.34
KvarQ: targeted and direct variant calling from fastq reads of bacterial genomes. BMC Genomics (2014) 1.19
Integration of published information into a resistance-associated mutation database for Mycobacterium tuberculosis. J Infect Dis (2015) 1.06
Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PLoS One (2015) 1.02
Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother (2015) 0.94
Evaluation of pyrosequencing for detecting extensively drug-resistant Mycobacterium tuberculosis among clinical isolates from four high-burden countries. Antimicrob Agents Chemother (2014) 0.93
Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates. Emerg Microbes Infect (2015) 0.93
Detection of Low-Level Mixed-Population Drug Resistance in Mycobacterium tuberculosis Using High Fidelity Amplicon Sequencing. PLoS One (2015) 0.93
Integrated microfluidic card with TaqMan probes and high-resolution melt analysis to detect tuberculosis drug resistance mutations across 10 genes. MBio (2015) 0.92
Comparative Study of Eis-like Enzymes from Pathogenic and Nonpathogenic Bacteria. ACS Infect Dis (2015) 0.91
Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review. PLoS One (2015) 0.90
Performance Comparison of Three Rapid Tests for the Diagnosis of Drug-Resistant Tuberculosis. PLoS One (2015) 0.89
Prevalence of Tuberculosis, Drug Susceptibility Testing, and Genotyping of Mycobacterial Isolates from Pulmonary Tuberculosis Patients in Dessie, Ethiopia. Tuberc Res Treat (2015) 0.87
Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations. Int J Tuberc Lung Dis (2015) 0.85
Genetic Determinants of Drug Resistance in Mycobacterium tuberculosis and Their Diagnostic Value. Am J Respir Crit Care Med (2016) 0.84
Draft Genome Sequence of the First Isolate of Extensively Drug-Resistant Mycobacterium tuberculosis in New Zealand. Genome Announc (2014) 0.83
Draft Genome Sequence of a Multidrug-Resistant New Zealand Isolate of Mycobacterium tuberculosis Lineage 3. Genome Announc (2014) 0.80
Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape. Antimicrob Agents Chemother (2016) 0.80
Phenotypic and genotypic diversity in a multinational sample of drug-resistant Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis (2015) 0.80
Disparities in capreomycin resistance levels associated with the rrs A1401G mutation in clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2014) 0.79
Rapid Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates Directly from Clinical Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study. J Clin Microbiol (2016) 0.77
Highly multiplexed, ten-color detection of isoniazid, fluoroquinolone, amikacin and kanamycin resistant tuberculosis in an automated assay suitable for point-of-care use. J Clin Microbiol (2016) 0.76
Draft Genome Sequence of the First Isolate of Extensively Drug-Resistant Mycobacterium tuberculosis in Ireland. Genome Announc (2014) 0.75
Draft Genome Sequence of a Drug-Susceptible New Zealand Isolate of Mycobacterium tuberculosis Lineage 3. Genome Announc (2015) 0.75
Primary Capreomycin Resistance Is Common and Associated With Early Mortality in Patients With Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr (2015) 0.75
The potential of a multiplex high-throughput molecular assay for early detection of first and second line tuberculosis drug resistance mutations to improve infection control and reduce costs: a decision analytical modeling study. BMC Infect Dis (2015) 0.75
Impact of gyrB and eis Mutations in Improving Detection of Second-Line-Drug Resistance among Mycobacterium tuberculosis Isolates from Georgia. Antimicrob Agents Chemother (2017) 0.75
Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med (1998) 20.81
Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2011) 4.55
GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J (2008) 4.32
Tuberculosis drug resistance mutation database. PLoS Med (2009) 4.13
Confidence intervals for a binomial proportion. Stat Med (1993) 3.62
Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol (2009) 3.08
Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol (2013) 2.89
The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One (2012) 2.88
Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis (2012) 2.78
Aerial dissemination of pulmonary tuberculosis. A two-year study of contagion in a tuberculosis ward. 1959. Am J Epidemiol (1995) 2.40
GeneXpert--a game-changer for tuberculosis control? PLoS Med (2011) 2.38
A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother (2012) 2.16
The infectiousness of tuberculosis patients coinfected with HIV. PLoS Med (2008) 2.08
Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol (2013) 1.99
Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One (2012) 1.93
Molecular determinants of drug resistance in tuberculosis. Int J Tuberc Lung Dis (2000) 1.77
Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. Int J Tuberc Lung Dis (2008) 1.70
Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing. J Antimicrob Chemother (2009) 1.69
Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ (2012) 1.60
Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens. J Clin Microbiol (2013) 1.43
Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing. J Clin Microbiol (2012) 1.39
Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa. Emerg Infect Dis (2011) 1.35
Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs. J Clin Microbiol (2012) 1.32
Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. Int J Tuberc Lung Dis (2011) 1.30
Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis. Tuberculosis (Edinb) (2011) 1.28
Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J Clin Microbiol (2010) 1.24
Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother (2011) 1.20
Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother (2013) 1.19
The role of eis mutations in the development of kanamycin resistance in Mycobacterium tuberculosis isolates from the Moscow region. J Antimicrob Chemother (2012) 1.14
Isoniazid-resistance conferring mutations in Mycobacterium tuberculosis KatG: catalase, peroxidase, and INH-NADH adduct formation activities. Protein Sci (2010) 1.08
Mechanisms of drug resistance in Mycobacterium tuberculosis and current status of rapid molecular diagnostic testing. Acta Trop (2011) 1.05
Pyrosequencing for rapid molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol (2011) 1.01
Phenotypically occult multidrug-resistant Mycobacterium tuberculosis: dilemmas in diagnosis and treatment. J Antimicrob Chemother (2013) 0.93
A systematic review of rapid drug susceptibility tests for multidrug-resistant tuberculosis using rifampin resistance as a surrogate. Expert Opin Med Diagn (2009) 0.93
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med (2007) 33.18
Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med (2010) 32.89
Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial. Lancet (2012) 7.01
A gene wiki for community annotation of gene function. PLoS Biol (2008) 6.60
Patients with active tuberculosis often have different strains in the same sputum specimen. Am J Respir Crit Care Med (2003) 5.22
Totally drug-resistant tuberculosis in India. Clin Infect Dis (2011) 4.31
Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med (2011) 4.21
Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol (2002) 4.20
Coccidioidomycosis. Clin Infect Dis (2005) 3.88
Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med (2005) 3.75
Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis? J Clin Microbiol (2011) 3.69
The Gene Wiki: community intelligence applied to human gene annotation. Nucleic Acids Res (2009) 3.51
Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol (2003) 3.29
An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med (2011) 2.70
Evaluation of an HIV nucleic acid testing program with automated Internet and voicemail systems to deliver results. Ann Intern Med (2010) 2.69
Developing an HIV behavioral surveillance system for injecting drug users: the National HIV Behavioral Surveillance System. Public Health Rep (2007) 2.69
Sensitive, specific polymorphism discovery in bacteria using massively parallel sequencing. Nat Methods (2008) 2.61
New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised. J Assoc Physicians India (2010) 2.60
Update and overview of practical epidemiologic aspects of HIV/AIDS among injection drug users in the United States. J Urban Health (2006) 2.42
Incidence of multidrug-resistant tuberculosis in urban and rural India and implications for prevention. Clin Infect Dis (2003) 2.38
Successful management of highly drug resistant tuberculosis with individualised drug susceptibility testing. J Assoc Physicians India (2014) 2.34
Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol (2006) 2.30
Ethical and regulatory considerations in HIV prevention studies employing respondent-driven sampling. Int J Drug Policy (2008) 2.15
Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis (2010) 2.14
HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog (2010) 2.12
Hepatitis C virus transmission from an anesthesiologist to a patient. Arch Intern Med (2002) 2.11
CHD8 is an ATP-dependent chromatin remodeling factor that regulates beta-catenin target genes. Mol Cell Biol (2008) 2.10
Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep (2007) 2.04
Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology (2014) 2.00
Acid-fast bacilli culture positivity and drug resistance in abdominal tuberculosis in Mumbai, India. Indian J Gastroenterol (2014) 2.00
The Accuracy of Ultrasonography on the Location of Lipomas in the Forehead. Dermatol Surg (2016) 2.00
Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex. J Clin Microbiol (2009) 1.94
Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One (2012) 1.93
Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet (2013) 1.93
Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. Blood (2009) 1.89
Characterization of the Manila family of Mycobacterium tuberculosis. J Clin Microbiol (2003) 1.89
Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med (2011) 1.87
Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis (2008) 1.86
Does bleach disinfection of syringes protect against hepatitis C infection among young adult injection drug users? Epidemiology (2002) 1.83
Molecular characterization of methicillin-resistant Staphylococcus aureus with emergence of epidemic clones of sequence type (ST) 22 and ST 772 in Mumbai, India. J Clin Microbiol (2010) 1.83
Tuberculosis and illicit drug use: review and update. Clin Infect Dis (2009) 1.76
Radiation monotherapy as regional treatment for lymph node-positive Merkel cell carcinoma. Cancer (2010) 1.74
Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India. PLoS One (2011) 1.70
A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. Am J Respir Crit Care Med (2011) 1.66
Rapid detection of isoniazid and rifampin resistance mutations in Mycobacterium tuberculosis complex from cultures or smear-positive sputa by use of molecular beacons. J Clin Microbiol (2004) 1.66
gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother (2012) 1.65
Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health (2004) 1.62
The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks. PLoS One (2013) 1.62
Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem (2009) 1.58
A survey of health professions students for knowledge, attitudes, and confidence about tuberculosis, 2005. BMC Public Health (2007) 1.57
HIV prevalence, risk behaviors, and high-risk sexual and injection networks among young women injectors who have sex with women. Am J Public Health (2003) 1.55
The non-clonality of drug resistance in Beijing-genotype isolates of Mycobacterium tuberculosis from the Western Cape of South Africa. BMC Genomics (2010) 1.54
Translational efficiency of a non-AUG initiation codon is significantly affected by its sequence context in yeast. J Biol Chem (2007) 1.53
A high-resolution linkage map for comparative genome analysis and QTL fine mapping in Asian seabass, Lates calcarifer. BMC Genomics (2011) 1.53
The role of IS6110 in the evolution of Mycobacterium tuberculosis. Tuberculosis (Edinb) (2007) 1.53
Perceived risk, peer influences, and injection partner type predict receptive syringe sharing among young adult injection drug users in five U.S. cities. Drug Alcohol Depend (2007) 1.50
High incidence of the Beijing genotype among multidrug-resistant isolates of Mycobacterium tuberculosis in a tertiary care center in Mumbai, India. Clin Infect Dis (2005) 1.47
Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis (2011) 1.46
Cross-border paid plasma donation among injection drug users in two Mexico-U.S. border cities. Int J Drug Policy (2009) 1.45
Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer. Int J Cancer (2014) 1.45
Strain dyssynchrony index correlates with improvement in left ventricular volume after cardiac resynchronization therapy better than tissue velocity dyssynchrony indexes. Circ Cardiovasc Imaging (2008) 1.44
A microsatellite linkage map of Barramundi, Lates calcarifer. Genetics (2006) 1.44
Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens. J Clin Microbiol (2013) 1.43
Mortality risk among recent-onset injection drug users in five U.S. cities. Subst Use Misuse (2008) 1.39
Prevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the U.S. Salud Publica Mex (2007) 1.38
Empirical comparison of cross-platform normalization methods for gene expression data. BMC Bioinformatics (2011) 1.35
Prevalence and correlates of chlamydia trachomatis, neisseria gonorrhoeae, trichomonas vaginalis infections, and bacterial vaginosis among a cohort of young injection drug users in Baltimore, Maryland. Sex Transm Dis (2005) 1.34
Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy. Eur Heart J (2012) 1.33
Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs. J Clin Microbiol (2012) 1.32
Prevalence and correlates of indirect sharing practices among young adult injection drug users in five U.S. cities. Drug Alcohol Depend (2007) 1.31
Housing status and associated differences in HIV risk behaviors among young injection drug users (IDUs). AIDS Behav (2007) 1.31
Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2002) 1.30
Problematic use of prescription-type opioids prior to heroin use among young heroin injectors. Subst Abuse Rehabil (2011) 1.30
Multicenter evaluation of reverse line blot assay for detection of drug resistance in Mycobacterium tuberculosis clinical isolates. J Microbiol Methods (2004) 1.29
Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microb Drug Resist (2011) 1.29
Are prolonged/continuous infusions of β-lactams for all? Clin Infect Dis (2013) 1.28
Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. Infect Genet Evol (2011) 1.27
Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex. Cancer Cell (2011) 1.25
Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med (2006) 1.24
The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004. Prev Med (2009) 1.23
Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis (2006) 1.23
Selection strategies for the establishment of recombinant Chinese hamster ovary cell line with dihydrofolate reductase-mediated gene amplification. Appl Microbiol Biotechnol (2005) 1.22
Evaluating the impact of Mexico's drug policy reforms on people who inject drugs in Tijuana, B.C., Mexico, and San Diego, CA, United States: a binational mixed methods research agenda. Harm Reduct J (2014) 1.22
The expanded criteria donor dilemma in cadaveric renal transplantation. Transplantation (2003) 1.22
Distributive syringe sharing among young adult injection drug users in five U.S. cities. Drug Alcohol Depend (2007) 1.21
Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18-30 years, 1994-2004. J Urban Health (2007) 1.21
Epidemic spread of multidrug-resistant tuberculosis in Johannesburg, South Africa. J Clin Microbiol (2013) 1.20
A first generation microsatellite- and SNP-based linkage map of Jatropha. PLoS One (2011) 1.19
TrkC plays an essential role in breast tumor growth and metastasis. Carcinogenesis (2010) 1.18
Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons? PLoS One (2010) 1.18
Multidrug-resistant tuberculosis in Mumbai: it's only getting worse. Int J Tuberc Lung Dis (2006) 1.18
Association between injection practices and duration of injection among recently initiated injection drug users. Drug Alcohol Depend (2004) 1.17
Frequency of insomnia report in patients with obstructive sleep apnoea hypopnea syndrome (OSAHS). Sleep Med (2004) 1.17
High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug Alcohol Depend (2005) 1.17
Primary gastric choriocarcinoma: two case reports and review of the literatures. Cancer Res Treat (2008) 1.17
Detecting drug-resistant tuberculosis: the importance of rapid testing. Mol Diagn Ther (2011) 1.16